Drug Profile
Research programme: PARP-1 inhibitors - Nerviano Medical Sciences
Alternative Names: NMS-P118Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Nerviano Medical Sciences
- Class Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Italy (PO)